
Exosome Liquid Biopsy for Earliest Pancreatic Cancer Detection
An interview with: Ajay Goel PhD, Chair of the Molecular Diagnostics and Experimental Therapeutics Department, Beckman Research Institute, City of Hope, Los Angeles California. SAN DIEGO—The prospect
An interview with:
Ajay Goel PhD, Chair of the Molecular Diagnostics and Experimental Therapeutics Department, Beckman Research Institute, City of Hope, Los Angeles California.
SAN DIEGO—The prospect of detecting pancreatic cancer at very early stages, when cure may be possible, is now being held out by research showing that the sub-cellular molecules called “exosomes” (shed into the bloodstream by cancer cells) can be analyzed to get very early diagnosis of the disease.
Study results using liquid biopsy to test for exosomes were reported at the 2024 American Association for Cancer Research Annual Meeting in San Diego. After his talk at the conference the senior author of the research, Ajay Goel, who is Chair Molecular Diagnostics and Experimental Therapeutics at the Beckman Research Institute, in City of Hope, Los Angeles, called in to Audio Journal of Oncology studio to tell us more about this exciting new science and its clinical implications:
Sarah Maxwell, Audio Journal of Oncology:
“A new non-invasive test, for pancreatic cancer, from liquid biopsy, could soon make it possible to detect the disease at stages when early intervention could greatly extend life, and even make cure possible. The tests checks for the presence of “exosomes” — circulating fragments of cancer cells — that can give early warning of a developing tumor.
At the American Association for Cancer Research Annual Meeting in San Diego, The Audio Journal of Oncology heard from Ajay Goel, senior author of the study who is Chair of the Molecular Diagnostics and Experimental Therapeutics Department at City of Hope in Los Angeles CA.
Ajay Goel PhD, Chair of the Molecular Diagnostics and Experimental Therapeutics Department, Beckman Research Institute, City of Hope, Los Angeles California:
IN: “Exosomes are essentially small extra-cellular vesicles released by the cancer cells………OUT: ……here in San Diego at the American Association for Cancer Research.” 13:09 secs.
AACR Abstract TITLE:
“An exosome-based liquid biopsy for non-invasive, early detection of patients with pancreatic ductal adenocarcinoma: A multicenter and prospective study”
Next in AACR 2024
All 4 interviewsInterview 3 of 4

Long Remissions with Bispecific T-cell Engager Antibody Therapy for Patients with Relapsed Multiple Myeloma
An interview with: Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New
Related Episodes

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?
SAN DIEGO, USA—The importance of gamma delta T-cells in the progression of cutaneous metastatic melanoma was highlighted at the 2026 Annual Meeting of the American Association for Cancer Research. Epidemiological evidence of a relationship between these very specialized cells and the age-dependency of cancer progression has now been linked to powerful laboratory-based in-vivo studies suggesting a potential role of gamma delta T-cells as components of cancer immunotherapy. Peter Goodwin talked with first author of the research, Mitchell E Fane, Assistant Professor at the Fox Chase Cancer Center’s Cancer Signaling and Microenvironment Program in Philadelphia, USA:

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma
BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma An interview with: Omar Nadeem MD, Medical Oncologist and Clinical Investigator, Dana-Farber Ca